Sugi Predict

Sugi Predict / Compounds / SCHEMBL2942990

SCHEMBL2942990

SCHEMBL2942990

O=C(Oc1cc(CN2CC(=O)N(c3ccc(S(=O)(=O)C(F)(F)F)cc3)C2=O)ccn1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PPARD Q03181 2/20 0.41
▸ PPARA Q07869 2/20 0.41
▸ ENPP2 Q13822 2/20 0.39
▸ IGF1R P08069 3/20 0.38
▸ PPARG P37231 1/20 0.37
▸ TAS2R8 Q9NYW2 3/20 0.36
▸ KMT2A Q03164 5/20 0.35
▸ USP2 O75604 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ CTSG P08311 1/20 0.33
▸ CMA1 P23946 1/20 0.33
▸ MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940546 0.87 PPARD (0.44) PPARDPPARAENPP2PPARGTAS2R8
SCHEMBL2937720 0.86 ENPP2 (0.41) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2941254 0.86 ENPP2 (0.41) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2935198 0.86 IGF1R (0.47) PPARDPPARAENPP2IGF1R
SCHEMBL2932332 0.85 PPARD (0.42) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2938148 0.84 PPARD (0.41) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2940436 0.83 IGF1R (0.42) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2943201 0.83 ENPP2 (0.48) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2942200 0.83 IGF1R (0.47) PPARDPPARAENPP2IGF1RPPARG
SCHEMBL2935703 0.83 RAB9A (0.41) PPARDPPARAENPP2IGF1RPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 PPARD 3189/4885PPARA 4338/4885ENPP2 3905/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA PPARD 3572/4885PPARA 4692/4885ENPP2 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.